Skip to main navigation
Skip to content

Top Bar

  • info@eledon.com
  • +1 949.238.8090

Main navigation

  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Governance
  • R&D
    • R&D Overview
    • CD40L Pathway
    • Pipeline
    • AT-1501
    • Phase 1 KLH Challenge
  • Investors
    • News
    • Events
    • Presentations
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
    • Contact
  • Join the team
  • Contact Us

Investors

Investor Relations

  • Investors
  • News
  • Events
  • Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor FAQs
  • Contact Investor Relations

News


Date Title
01/19/2021 Summary ToggleEledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
01/04/2021 Summary ToggleNovus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook
12/22/2020 Summary ToggleNovus Therapeutics Announces Results of Special Meeting of Stockholders
12/09/2020 Summary ToggleNovus Therapeutics Appoints June Lee, M.D., to Board of Directors
11/16/2020 Summary ToggleNovus Therapeutics Reports Third Quarter 2020 Financial Results
11/10/2020 Summary ToggleNovus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16
11/02/2020 Summary ToggleNovus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
10/02/2020 Summary ToggleNovus Therapeutics Announces One-for-Eighteen Reverse Stock Split
09/15/2020 Summary ToggleNovus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
09/14/2020 Summary ToggleNovus Therapeutics Announces Acquisition of Anelixis Therapeutics

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 69 results

Toolkit

Print Page Email Alerts RSS Feeds Contact

Footer

Quick links

  • Home
  • About Us
  • CD40L Pathway
  • Pipeline
  • AT-1501
  • KLH Challenge
  • Contact Us

Footer Investor Links

 

  • Investors
  • Press Releases
  • Governance
  • Stock Information
  • SEC Filings
  • Investor Email List
© 2021 Eledon Pharmaceuticals, Inc. - All Rights Reserved.